0.00Open0.00Pre Close0 Volume0 Open Interest370.00Strike Price0.00Turnover85.14%IV-46.92%PremiumDec 20, 2024Expiry Date118.16Intrinsic Value100Multiplier17DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9890Delta0.0016Gamma2.13Leverage Ratio-0.0230Theta-0.0329Rho-2.11Eff Leverage0.0143Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet